Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan Designation

Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan Designation

Pancreatic cancer has a dismal prognosis and only a few treatment options are available. In the European Union, pancreatic cancer classifies as a rare disease, allowing drug developers to apply for orphan medicinal product (OMP) designation. The aim of this study was to provide more detail on OMPs f...

Full description

Bibliographic Details
Main Authors: Jorn Mulder, Tobias van Rossum, Segundo Mariz, Armando Magrelli, Anthonius de Boer, Anna M. G. Pasmooij, Violeta Stoyanova-Beninska
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-12-01
Series:Frontiers in Oncology
Subjects:
orphan designation
rare disease
pancreatic cancer
european medicines agency
drug development
committee for orphan medicinal products
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.809035/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.809035/full

Similar Items